FindTrial
Sign In

Clinical study of oxelidine, a G-protein-biased opioid receptor agonist, for postoperative analgesia in elderly patients undergoing laparoscopic radical resection of rectal cancer

Clinical study of oxelidine, a G-protein-biased opioid receptor agonist, for postoperative analgesia in elderly patients undergoing laparoscopic radical resection of rectal cancer

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400094171
Enrollment
Unknown
Registered
2024-12-18
Start date
2024-10-17
Completion date
Unknown
Last updated
2025-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rectal cancer

Interventions

Oxeridine controlled intravenous analgesia group (group S):30min before the end of the operation, intravenous oxelidine 1mg was injected intravenously. PCIA immediately after entering PACU Group S ana
Sufentanil controlled intravenous analgesia group (group C):30min before the end of the operation, Sufentanil was injected intravenously with 0.1µg/kg PCIA immediately after entering PACU Group C anal
Oxeridine + sufentanil controlled intravenous analgesia group (group A):30min before the end of the operation, intravenous oxelidine 1mg was injected intravenously. PCIA immediately after entering PAC

Sponsors

Tianjin Cancer Hospital Airport Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients with definite diagnosis and need laparoscopic radical resection of rectal cancer; Good cardiopulmonary function, no surgical contraindications; Informed consent, voluntary participation.

Exclusion criteria

Exclusion criteria: Participating in other clinical trials in the past 3 months; Those who do not cooperate or ask for withdrawal during the research process; American Society of Anesthesiologists (ASA) Grade >?; Severe cardiovascular and cerebrovascular diseases; Abnormal liver and kidney function; Lung infection; Increased intracranial pressure; Poorly controlled or untreated hypertension (arterial hypertension, resting systolic/diastolic blood pressure greater than 180/100 mmHg, 1mmHg= 0.133kPa); History of gastrointestinal ulcer or bleeding; Bleeding tendency; Hyperthyroidism; Pulmonary hypertension; Speech impediment or mental illness; A long history of opioid use.

Design outcomes

Primary

MeasureTime frame
NRS pain score 24 hours after surgery;Incidence of adverse reactions;—

Secondary

MeasureTime frame
NRS pain score 48 hours after surgery;Total use of postoperative analgesic drugs;Postoperative recovery time;—

Countries

China

Contacts

Public ContactPeng Zhang

Tianjin Cancer Hospital Airport Hospital

452637954@qq.com+86 138 2068 6080

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026